Adding New Drugs for HIV Infected Patients Failing Current Therapy
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1/Phase 2
Even though powerful anti-HIV drug combinations have been successful in patients with little
or no prior anti-HIV therapy, studies have shown that these treatments are less effective in
patients who have been treated with nucleoside analogues. This study will test the safety and
effectiveness of adding one or two new drugs to a personalized anti-HIV regimen for patients
whose previous HIV treatments have failed.
A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
The purpose of this study is to evaluate the safety, efficacy, and side effects of
beta-D-2,6-diaminopurine dioxolane (DAPD) compared to DAPD plus mycophenolate mofetil (MMF)
when these drugs are added to the anti-HIV treatment regimens of people infected with HIV.
Some studies have shown that DAPD and MMF can help fight HIV. However, neither DAPD nor MMF
has been approved by the Food and Drug Administration for treating HIV infection. This study
will help doctors decide if DAPD and MMF are good drugs for treating HIV.
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
Completed
RFS Pharma, LLC
Phase 1/Phase 2
The purpose of this study is to determine the short term safety, tolerance, and antiviral
effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage
for AZT can be reduced, potentially decreasing side effects, while maintaining antiviral
effects.
Study hypothesis: DADP in combination with AZT is safe and effective, and AZT dosing may be
reduced, resulting in lower levels of AZT-monophosphate associated with toxicity and
maintaining levels of AZT-triphosphate associated with efficacy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
